Iris Dotan
Rabin Medical Center
380 Papers
1.1K Citations
Iris Dotan is an academic researcher from Rabin Medical Center. The author has contributed to research in topics: Medicine & Inflammatory bowel disease. The author has an hindex of 48, co-authored 267 publications. Previous affiliations of Iris Dotan include Icahn School of Medicine at Mount Sinai & Humboldt University of Berlin.
Chat about Author
Papers
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
1.6K
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Dan Turner,Amanda Ricciuto,Ayanna Lewis,Ferdinando D'Amico,Jasbir Dhaliwal,Anne M. Griffiths,Dominik Bettenworth,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Jürgen Schölmerich,Willem A. Bemelman,Silvio Danese,Jean Yves Mary,David T. Rubin,Jean-Frederic Colombel,Laurent Peyrin-Biroulet,Iris Dotan,Maria T. Abreu,Axel Dignass +19 more
TL;DR: In a recent survey of 89 members of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD), a systematic review of the literature and iterative surveys of 89 IOIBD members, recommendations were drafted and modified in 2 surveys and 2 voting rounds as mentioned in this paper.
1.6K
Autophagic and tumour suppressor activity of a novel Beclin1-binding protein UVRAG
TL;DR: UVRAG is identified as an essential component of the Beclin1–PI(3)KC3 lipid kinase complex that is an important signalling checkpoint for autophagy and tumour-cell growth.
1K
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Severine Vermeire,Sharon O'Byrne,Mary E. Keir,Marna Williams,Timothy T. Lu,John C. Mansfield,Christopher A. Lamb,Brian G. Feagan,Julián Panés,Azucena Salas,Daniel C. Baumgart,Stefan Schreiber,Iris Dotan,William J. Sandborn,Gaik W. Tew,Diana Luca,Meina T. Tang,Lauri Diehl,Jeffrey Eastham-Anderson,Gert De Hertogh,Clémentine Perrier,Jackson G. Egen,John A. Kirby,Gert Van Assche,Gert Van Assche,Paul Rutgeerts +25 more
TL;DR: Etrolizumab was more likely to lead to clinical remission at week 10 than was placebo, and blockade of both α4β7 and αEβ7 might provide a unique therapeutic approach for the treatment of ulcerative colitis, and phase 3 studies have been planned.
466
Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study
Timna Naftali,Lihi Bar-Lev Schleider,Iris Dotan,Ephraim Philip Lansky,Fabiana Benjaminov,Fred M. Konikoff +5 more
TL;DR: Although the primary end point of the study was not achieved, a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 10 of 11 patients with active Crohn's disease, compared with placebo, without side effects.
312